Eukles Asset Management Sells 303 Shares of Illumina, Inc. (NASDAQ:ILMN)

Eukles Asset Management reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,876 shares of the life sciences company’s stock after selling 303 shares during the quarter. Eukles Asset Management’s holdings in Illumina were worth $785,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Cetera Investment Advisers grew its stake in shares of Illumina by 25.8% during the 2nd quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock valued at $1,919,000 after acquiring an additional 3,767 shares during the period. CWM LLC grew its stake in shares of Illumina by 179.8% during the 3rd quarter. CWM LLC now owns 16,207 shares of the life sciences company’s stock valued at $2,114,000 after acquiring an additional 10,414 shares during the period. UMB Bank n.a. grew its stake in shares of Illumina by 23.7% during the 3rd quarter. UMB Bank n.a. now owns 1,659 shares of the life sciences company’s stock valued at $216,000 after acquiring an additional 318 shares during the period. Livforsakringsbolaget Skandia Omsesidigt grew its stake in shares of Illumina by 323.9% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,047 shares of the life sciences company’s stock valued at $136,000 after acquiring an additional 800 shares during the period. Finally, Valeo Financial Advisors LLC bought a new position in shares of Illumina during the 3rd quarter valued at approximately $276,000. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Leerink Partners boosted their price objective on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Piper Sandler dropped their price target on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. UBS Group upped their price target on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Guggenheim dropped their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday. Finally, Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $159.90.

Illumina Stock Performance

NASDAQ:ILMN opened at $111.06 on Monday. The stock’s fifty day moving average is $136.70 and its 200 day moving average is $135.43. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The firm has a market capitalization of $17.61 billion, a PE ratio of -14.46 and a beta of 1.10. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.42 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.